Spinal muscular atrophy (SMA) is one of the most important conditions on modern carrier screening panels — and for good reason.
What is SMA?
It’s a genetic disease that affects the motor neurons — the nerves that control muscle movement. Without these neurons, muscles weaken over time. Babies with the most severe type (Type 1) often struggle to sit, breathe, or swallow, and life expectancy is shortened.
Why it’s included in screening
-
Carrier frequency is about 1 in 40 — that’s common enough to warrant universal screening.
-
If both partners are carriers, each pregnancy has a 1 in 4 chance of being affected.
-
Early awareness allows families to plan reproductive choices.
Here’s the good news:
In the last few years, treatments for SMA have revolutionized the outlook. Drugs like Spinraza (2016), Zolgensma (2019, a one-time gene therapy), and Evrysdi (2020) have turned SMA from a fatal condition into one where children can sit, walk, and live longer, fuller lives.
Why screening still matters
Even with treatments, prevention and planning remain crucial. Families who know they’re carriers can:
-
Pursue IVF with embryo testing
-
Consider donor options
-
Enter pregnancy knowing they can prepare for early intervention if needed
SMA is a story of hope — where science, advocacy, and family planning all come together.
Takeaway: SMA screening empowers families with knowledge, and new treatments add hope for better futures.